ASBP
Aspire Biopharma Holdings, Inc. (ASBP) SWOT Analysis Analysis (2026)
Strengths
Strong liquidity with a current ratio of 7.99 and cash ratio of 7.22, supported by cash per share of 11.72.
Balance sheet remains debt-light, with debt-to-assets and debt-to-equity both at 0 and net current asset value of 11.68M.
Shares screen below book value at 0.79x P/B and below net-net value, suggesting asset-backed downside support.
Weaknesses
Profitability remains deeply negative, with net profit margin at -113.14% and EBIT margin at -64.66%.
Operating efficiency is very weak, with asset turnover at 0.007 and operating cash flow per share at -6.92.
Cash generation is poor despite reported liquidity, as operating cash flow is -4.26 and free cash flow per share is -6.92.
Opportunities
The stock trades at a low price-to-book multiple of 0.79x, leaving room for rerating if execution improves.
Net-net value of 10.14 per share and cash per share of 11.72 provide a tangible asset base that could support value-oriented upside.
If management can convert the current gross margin of 18.35% into sustainable operating leverage, earnings power could improve materially.
Threats
Sustained losses and negative operating cash flow increase the risk of dilution or further balance-sheet stress.
Interest coverage is negative at -0.76x, indicating limited ability to service financing costs from current operations.
Extremely weak turnover metrics, including inventory turnover of 0.28 and cash conversion cycle of -3129 days, point to severe working-capital distortion and execution risk.
Overall Score
Sources
- Company filings (10-K, 10-Q, investor presentations)
- Financial and market data providers
- Public news and industry information
🔒 Go Beyond This Framework
This is one of 10 institutional-grade frameworks Invetso runs on Aspire Biopharma Holdings, Inc.. Unlock the complete analysis — SWOT, Economic Moat, Porter’s Five Forces, Management, PESTLE and the Invetso Quality Score.

